Picture1.jpg
ONCOTELIC CLINICAL PRESENTATIONS AT SITC 2024
06 nov. 2024 10h47 HE | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at SITC 2024. Dr. Cynthia Lee, VP of R&D will be presenting Sapu...
Picture1.jpg
ONCOTELIC PUBLISHED ITS FOURTH PUBLICATION ON TGFB2 THERAPEUTICS
28 oct. 2024 08h00 HE | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its fourth publication of its TGFB2 series. Clinical data demonstrated that...
Picture1.jpg
ONCOTELIC PRESENTATION AT PRECISION IN DRUG DISCOVERY & PRECLINICAL SUMMIT SAN DIEGO 2024
23 oct. 2024 08h00 HE | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at Precision in Drug Discovery & Preclinical Summit. Dr. Wen-Han...
Picture1.jpg
ONCOTELIC TO PRESENT AT THE 20TH ANNUAL CONGRESS OF INTERNATIONAL DRUG DISCOVERY SCIENCE & TECHNOLOGY
11 juin 2024 08h10 HE | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its CEO- Dr. Vuong Trieu will speak at the 20th Annual Congress of International Drug...
Picture1.jpg
ONCOTELIC TO PARTICIPATE AT THE BIO INTERNATIONAL 2024 MEETING
30 mai 2024 09h55 HE | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its CEO- Dr. Vuong Trieu will be participating at the BIO International 2024 meeting...
Picture1.jpg
ONCOTELIC PRESENTING AT BIOPHARMA NEXUS CONFERENCE SAN DIEGO 2024
08 mai 2024 08h00 HE | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at Biopharma Nexus Conference. Dr. Andy Hu, Nanomedicine Manager,...
Picture1.jpg
Oncotelic Therapeutics, Inc. to Sell Its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc.
29 avr. 2024 07h00 HE | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today that it has entered into a binding...
Picture1.jpg
Linkage of Cancer and Lupus in Gliomas Patients
25 mars 2024 08h10 HE | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today the peer reviewed publication of Transforming Growth Factor Beta 2 (TGFB2) mRNA...
Picture1.jpg
Invitation to Participate in STOP-PC Clinical Trial
04 mars 2024 08h17 HE | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) invites participation in our STOP-PC clinical trial which is now open for recruitment. Additional...
Picture1.jpg
Oncotelic Therapeutics Announces Clinical Linkage of TGFB2 and IFNGR2 in Pediatric DMG Patients
16 janv. 2024 08h00 HE | Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today the peer reviewed publication of Transforming Growth Factor Beta 2 (TGFB2) and...